Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CHKA | P35790 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | NCF1 | P14598 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | PHGDH | O43175 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7542075 | 1.00 | TDP1 (0.44) | TDP1KDM4EHTTCHKALMNA | |
| SCHEMBL10303830 | 1.00 | TDP1 (0.44) | TDP1KDM4EHTTCHKALMNA | |
| SCHEMBL577660 | 1.00 | TDP1 (0.44) | TDP1KDM4EHTTCHKALMNA | |
| SCHEMBL1043117 | 1.00 | TDP1 (0.44) | TDP1KDM4EHTTCHKALMNA | |
| SCHEMBL82606 | 1.00 | — | — | |
| SCHEMBL19677597 | 1.00 | TDP1 (0.44) | TDP1KDM4EHTTCHKALMNA | |
| SCHEMBL1043845 | 1.00 | TDP1 (0.44) | TDP1KDM4EHTTCHKALMNA | |
| SCHEMBL10303827 | 1.00 | TDP1 (0.44) | TDP1KDM4EHTTCHKALMNA | |
| SCHEMBL22228576 | 0.96 | TDP1 (0.42) | TDP1KDM4EHTTCHKALMNA | |
| SCHEMBL10211088 | 0.95 | TDP1 (0.40) | TDP1KDM4EHTTCHKALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 865 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101997-A1 | CHEMICAL BINDING OF SURFACE POLYMER TO EPOXY MATERIAL | YIELD ENGINEERING SYSTEMS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20250319443-A1 | METHOD FOR MANUFACTURING A THIN-FILM COMPOSITE MEMBRANE FOR WATER TREATMENT, HAVING EXTREME ACID AND ALKALINE STABILITY | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2025-10-16 | — | — | US | claimed |
| CN-119976876-A | Cu-Fe-SSZ-13 molecular sieve, preparation method thereof, catalyst and application | 中化学科学技术研究有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-119859208-A | Binary free radical polymerization method | 上海交通大学 | 2025-04-22 | — | — | CN | claimed |
| EP-3042645-B2 | Dental composites with improved storage stability | IVOCLAR VIVADENT AG (LI) | 2025-03-12 | — | — | EP | claimed |
| CN-116082260-B | Catalyst, preparation method thereof and preparation method of aliphatic isocyanate polymer | 山东新和成精化科技有限公司 | 2025-01-28 | — | — | CN | claimed |
| US-20240368784-A1 | METHOD FOR MANUFACTURING A THIN FILM COMPOSITE MEMBRANE FOR ALKALINE WATER ELECTROLYSIS | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2024-11-07 | — | — | US | claimed |
| US-20240315930-A1 | PASTE-FORM TWO-PACK TYPE DENTAL CURABLE COMPOSITION | KURARAY NORITAKE DENTAL INC. (JP) | 2024-09-26 | — | — | US | claimed |
| EP-4413966-A1 | PASTE-FORM TWO-PART CURABLE COMPOSITION FOR DENTAL USE | Kuraray Noritake Dental Inc. (JP) | 2024-08-14 | — | — | EP | claimed |
| EP-4026870-B1 | METHOD FOR PRODUCING POROUS MICROSTRUCTURE | TANTTI LABORATORY INC (TW) | 2024-01-10 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0440520-A1 | Process for preparing polycarbosilanes in the presence of molten metallic sodium and sequestering agents | RHONE-POULENC CHIMIE (FR) | 1991-08-07 | — | — | EP | claimed |
| EP-0058505-B1 | PREPARATION OF ESTERS CONTAINING AN ALPHA-CYANO GROUP IN THE ALCOHOL PORTION OF THE ESTERS | FMC Corporation (US) | 1985-05-29 | — | — | EP | claimed |
| EP-0026542-B1 | PREPARATION OF ESTERS CONTAINING AN ALPHA CYANO GROUP IN THE ALCOHOL PORTION OF THE ESTER | FMC Corporation (US) | 1982-12-15 | — | — | EP | claimed |
| EP-0058505-A1 | Preparation of esters containing an alpha-cyano group in the alcohol portion of the esters | FMC Corporation (US) | 1982-08-25 | — | — | EP | claimed |
| US-4322534-A | Preparation of esters | FMC CORPORATION (US) | 1982-03-30 | — | — | US | claimed |
| EP-0026542-A1 | Preparation of esters containing an alpha cyano group in the alcohol portion of the ester | FMC Corporation (US) | 1981-04-08 | — | — | EP | claimed |
| US-4254050-A | PREPARATION OF ALPHA-CYANO ESTERS BY REACTING AN ACY HALIDE WITH AN ALDEHYDE IN A CYANIDE SALT SOLUTION | FMC CORPORATION (US) | 1981-03-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240315930-A1 | PASTE-FORM TWO-PACK TYPE DENTAL CURABLE COMPOSITION | TIPRL, STAU1, CALCOCO2 | TDP1 586/4885KDM4E 1987/4885HTT 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.